A Case of Intestinal Behcet's Disease Complicated Enterocutanous Fistula with a Good Response to Adalimumab.
10.4078/jrd.2012.19.3.147
- Author:
IL Hwan OH
1
;
Jin Ok KIM
;
Young Jae BYUN
;
Yoon Kyoung SUNG
;
Chan Bum CHOI
;
Tae Hwan KIM
;
Jae Bum JUN
;
Wan Sik UHM
Author Information
1. Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. wsuhm@hanyang.co.kr
- Publication Type:Case Report
- Keywords:
Behcet's disease;
Intestine;
TNF-alpha;
Adalimumab
- MeSH:
Antibodies, Monoclonal, Humanized;
Fistula;
Hemorrhage;
Humans;
Intestinal Perforation;
Intestines;
Prognosis;
Skin;
Stomatitis, Aphthous;
Tumor Necrosis Factor-alpha;
Ulcer;
Uveitis;
Adalimumab
- From:Journal of Rheumatic Diseases
2012;19(3):147-151
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Behcet's disease (BD) is a multisystemic disorder, which is characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesion. Although intestinal involvement is an uncommon manifestation of the BD, it leads to a poor prognosis, as a result of a high complication, such as intestinal perforation, fistula formation, and massive hemorrhage. Intestinal BD has the tendency for the resistance to conventional medical treatment, and it often requires a surgical intervention because of severe complication. Although the causes of intestinal BD are unknown, some studies show that tumor necrosis factor Alpha (TNF-alpha) plays a key role in the pathogenesis of BD. Therefore, anti-TNF-alpha monoclonal antibody, such as adalimumab, is one of the useful treatment for refractory and relapsed intestinal BD. We describe a patient who had intestinal BD complicated enterocutanous fistula with a good response to adalimumab.
